Sign inTry free

Spero Therapeutics (SPRO) stock

Infection treatments , market cap $73.4M

$1.17
-1.68%

Pre-market. Prices 16 minutes old, as of 6:01 AM ET. Pro members see real-⁠time prices.

Quality Score
0
Below Average
In its industry
#135of 308
Biotech

SPRO's Quality Score was unchanged on Wed, Oct 7, at 0.

Holding it back: below its 200-day since June, down 44% in a year. 3 more reasons behind SPRO's 0, for Pro members.

NextEarly 2027“…in IgG4-RD patients in Q2 2027; Innovent expects to initiate a Phase 2 trial in China for SjD by early 2027…”Trial start · 8-K, Jul 14

Follow SPRO's news. Pro members can get an alert when Spero Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when SPRO files newsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

What's next

Expected to report Thu Nov 12, after the close

After its last 4 reports it closed +3.6% on average, higher 2 of 4 times.

For Pro members

  • What would turn SPRO's score around: 6 things

What's next for SPRO

From Spero Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Early 2027“expects to advance SP001 into a Phase 2 study in IgG4-RD patients in Q2 2027; Innovent expects to initiate a Phase 2 trial in China for SjD by early 2027.”Trial start · 8-K, Jul 14

What it means: when a trial begins, or reaches the stage the company named.

Lead program
SP001

For Pro members: 1 more milestone and 34 filings.

Dilution on the horizon

  • Shelf registration (S-3, filed Aug 28, 2026)
  • At-the-market share sales program (S-3, filed Aug 28, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

CEO Esther Rajavelu sold 25,240 shares on May 4. 4 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Esther Rajavelu buys or sells

For Pro members: every trade, and Esther Rajavelu’s 12 filings and quotes.

Get an optional alert when SPRO files newsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 110 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why SPRO scores 0

Below AverageTrending down, 3 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +3Chart checks 3 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Size subtracts
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Run-up, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on SPRO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 6:01 AM ET, at least 15 minutes behind. How we rank stocks.

Alert me when SPRO's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on SPRO and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

SPRO has 3 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on SPRO, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1445.4

    Above 30, below 50.

  • MACD (12, 26, 9)Above signal

    Crossed above its signal line 45 sessions ago.

  • 50-day average$1.20

    The price is 2.5% below it.

  • 200-day average$2.09

    The price is 44.0% below it. The 50-day is below the 200-day, since Jul 21.

  • ADX 1429.1

    25 or more, with +DI above -DI.

  • Support$1.12

    Swing low from Aug 3, 3.8% below the price.

  • Resistance$1.24

    Swing high from Sep 2, 5.9% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $1.06 to $1.31.

  • Volume0.3x

    Against its 20-day average, for the time of day.

How SPRO ranks in Biotech

SPRO is #135 of 308 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does SPRO report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 35 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 12, 2026After close+5.9%+4.2%+3.4%
May 13, 2026After close0.0%+13.1%+7.8%
Mar 26, 2026After close-3.0%-1.7%+2.5%
Nov 13, 2025After close-2.0%-1.2%-7.4%

The gap is the next open against the close before the report; the reaction is where that session closed. SPRO closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

SPRO's officers and directors

Officers and directors with a Form 4 here in the last 12 months. Open one for their trades at every company.

2 more officers and directors file at SPRO. Each page above names the rest.

See insider trades by person

About Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

25 employeesCambridge, MAsperotherapeutics.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of SPRO's score, with the points and the reason
  • All 14 checks on SPRO and on all 3,283 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on SPRO
See all 14 checks on SPROSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders, and profits come straight from the SEC. That means Form 4 filings, 13F filings, and XBRL financial data on EDGAR. Where a company's SEC figures leave the Quality Score's sales, share count, or cash flow line empty, the score reads that figure from Massive's statements, and the Score tab says so. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch, and Yahoo Finance publish, shown as the headline, the source, and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.